Home › Companies › ALLO

Allogene Therapeutics

Market cap $256M 346.5M shares (10-Q, Nov 3, 2026) × $0.740 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. ALPHA3 corporate updateYear-end 2026ALPHA3 corporate update, Year-end 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Technology platforms

Dagger

Proprietary allogeneic CAR T platform technology incorporating CD70-targeting to address allogeneic rejection by targeting activated CD70-positive patient T cells; enables off-the-shelf CAR T development across oncology (hematological and solid tumors) and autoimmune disease; supports dual-CAR and site-specific genomic integration approaches.

Targets: CD70, BCMA, DLL3

Discontinued (1)

Capital (as filed)

Cash
$29.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$264M Sep 30, 2026
Long-term investments
$95.9M Sep 30, 2026
Operating cash flow
−$36.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$389M cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (12)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (12 calls)

Every verdict Biotech Distilled has published on Allogene Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Hold Allogene Therapeutics (ALLO) - Scientific Deep Dive for Lead and Pipeline Products The science is elegant but recent safety issues and protocol amendments introduce too much mechanistic risk to buy ahead of the April 2026 MRD clearance data; wait for the data to de-risk the asset.
  2. Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The Data Hit, The Raise Stung The ALPHA3 MRD interim cleared the prespecified benchmark cleanly, retiring the Conditioning Crisis bear case, and the safety profile is the off-the-shelf dream, though the dilutive raise and remaining IP overhang keep this lottery-ticket sized.
  3. Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The IP Sword Gets a Second Edge Clinical thesis still tracking after the April MRD data, but the IP overhang doubled with a second TALEN challenge from Life Technologies, and the ALLO-329 timeline slipped six months; maintaining lottery-ticket sizing.
  4. Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The Founder Hands Over the Keys The orderly CEO succession to the architect of the April MRD data introduces modest execution risk but does not change the clinical thesis, cash position, or IP overhang; maintaining lottery-ticket sizing.
  5. Watch UPDATE: Allogene Therapeutics (ALLO) - The ATM Arrives Two Months Early The $135M ATM filed two months after a fully funded raise, combined with authorized shares doubled to 800M, caps near-term upside and compresses per-share payoff at EFS; stepping back from speculative buy because the cap-table terms have moved, not because the science broke.
  6. Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The Solid Tumor Wildcard Prints The TRAVERSE JCO publication validates Dagger in a second indication with durable RCC responses and IEC-HS converted from lethal to manageable, creating a credible non-dilutive partnership path and favorable read-through to ALLO-329; asymmetry improved enough to re-earn the speculative buy label.
  7. Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The FDA Read the Same Data I Did RMAT and Fast Track granted after FDA reviewed the full ALPHA3 futility analysis, providing the first external non-Allogene validation of the MRD signal and shortening the regulatory path at the margin; maintaining speculative buy.
  8. Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The ATM They Didn't Use Zero shares sold under the ATM through a 14% rally repairs the specific cap-table objection that drove the June downgrade; enrollment execution beat guidance and manufacturing re-hiring is underway, supporting maintaining the lottery-ticket position.
  9. Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The CFO Walks Out With the ATM Still Loaded CFO retirement with no named successor adds a watch item on issuance behavior but contains no clinical or financial content that changes the thesis; maintaining speculative buy while monitoring the successor hire profile.
  10. Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - TPG Heads for the Exit TPG's full exit at $1.55 is a real sentiment negative and adds to a pattern of founding-era holders rotating out, but the clinical thesis, balance sheet, and catalyst path are unchanged, and the 18.7M-share overhang has now cleared.
  11. Hold UPDATE: Allogene Therapeutics (ALLO) - Trading Below Cash, Three Days From the Dagger Test Moving from accumulating to waiting for the ACR ALLO-329 data because the newly activated fludarabine arm adds real uncertainty to the Dagger story right before its first human test in autoimmune disease; the downgrade is not about the balance sheet.
  12. Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The Dagger Draws Blood, Not a Knockout ALLO-329 cleared the safety hurdle cleanly with zero DLTs, IEC-HS, ICANS, or GvHD in 18 patients and showed skin improvement in 8/10 scleroderma patients including without chemo, but partial B-cell depletion and a company reframe keep this a cautious upgrade to lottery-ticket sizing rather than a full conviction call.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (37)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

15 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)